NCT06613984View on ClinicalTrials.gov

Korean Post Marketing Surveillance for Comirnaty Injection (Bretovameran)

Active, not recruitingOBSERVATIONAL

Enrollment

660

Participants

Timeline

Start Date

October 11, 2024

Primary Completion Date

August 29, 2028

Study Completion Date

August 29, 2028

Conditions

COVID-19 Vaccination

Interventions

BIOLOGICAL

Bretovameran

Comirnaty Injection (Bretovameran) is administered intramuscularly as a single dose of 0.3 mL for individuals 12 years of age and older regardless of prior COVID-19 vaccination status.

Trial Locations (1)

Unknown

Pfizer, Seoul